Miracell Receives FDA 510(k) Clearance for SMART M-CELL PRP Concentration System and SMART M-CELL Bone Marrow Concentration System
Miracell has received FDA 510(k) clearance for its SMART M-CELL blood and bone marrow concentration systems and kits, an automated platform the company says uses patented separation technology to preserve cell viability while concentrating growth factors and stem cell-rich regenerative components for applications including orthopedics, wound healing, and regenerative medicine.
Key findings
- Miracell has received FDA 510(k) clearance for its SMART M-CELL system and its blood and bone marrow kits.
- The clearance was based on substantial equivalence to SmartPReP, a cell concentration system originally developed at Harvard Medical School.
Miracell has received FDA 510(k) clearance for its SMART M-CELL extraction system, along with the BSC Blood Kit and BMSC Bone Marrow Kit. The company says the automated platform separates and concentrates regenerative components from blood and bone marrow while maintaining cell viability.
Get Regen Report in your inbox
Weekly updates on regenerative medicine news, trials, and regulatory moves.
What the system does
SMART M-CELL selectively concentrates what Miracell calls Efficient Growth Factors from blood and bone marrow. According to the company, the output also includes a multi-cell composition containing growth factors, white blood cells, and SDF-1α (stromal cell-derived factor 1 alpha, a signaling protein involved in cell trafficking and tissue repair), intended to support tissue regeneration and functional recovery.
The company says the system is designed for high recovery rates and operational stability. The FDA clearance covers the integrated system, including both the centrifuge and the kit, not just individual components.
Regulatory and technical context
The clearance was granted based on substantial equivalence to SmartPReP, a concentration system originally developed by the Institute for Immunological Research at Harvard Medical School. Miracell says SmartPReP-based cell concentration technology has been supported by about 100 related publications and review articles.
Miracell also says preserving cellular sensitivity and biological characteristics during processing requires more than simple physical concentration. SMART M-CELL uses a proprietary system and kit design aimed at improving cell recovery and purity, and notes it previously received a U.S. patent in February 2024 for the centrifuge container used in the system.
Clinical context
The company points to published work around bone marrow aspirate concentrate (BMAC) and blood stem cell concentrate (BSC) in musculoskeletal care.
- In knee osteoarthritis, BMAC injections have demonstrated pain reduction and functional improvement.
- In rotator cuff tears, BMAC and BSC have been associated with increased cell proliferation, pain relief, and functional recovery.
- In cartilage defects and bone injury sites, studies have reported tissue regeneration and histological improvement following use of BMAC or BSC.
Beyond musculoskeletal uses, cell concentration approaches have also been explored in skin regeneration and aesthetics, diabetic ulcers, chronic wound healing, vascular and cardiovascular regeneration, and immune-related conditions.
Global rollout
Miracell says SMART M-CELL is currently the only FDA-cleared Efficient Growth Factors extraction system from Korea. The company adds that it has already secured regulatory approvals in multiple countries and is supplying SMART M-CELL and related kits in about 40 countries, including markets in Europe.
According to Miracell, additional regulatory approvals are in progress in Brazil and Taiwan, and the company plans to expand further in the U.S. following the FDA clearance.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
